6 results about "Leishmania" patented technology

The present invention relates to the use of parasites and extracellular vesicles obtained from parasites for cancer treatment. The aim of the present invention is to use parasites and extracellular vesicles obtained from parasites in cancer treatment and to load active substances onto the exosomes by using the drug loading capacity of the exosomes and thus to carry the specific drug directly to the target cancer cells without causing any side effects on healthy cells and thereby to increase the bioavailability of the drug to achieve the desired effect in the tumor-specific target area. Within the scope of the present invention, in particular, the infantile leishmania parasite is used as a source of extracellular vesicles.

The present application relates to glycoengineered bifunctional degradation derivatives, populations of glycoengineered bifunctional degradation derivatives, Leishmania host cells for producing the glycoengineered bifunctional degradation derivatives, methods for genetically engineering the Leishmania host cells, methods for culturing the Leishmania host cells, methods for making glycoengineered bifunctional degradation derivatives using the Leishmania host cells, and methods of using the glycoengineered bifunctional degradation derivatives. In particular, the glycoengineered bifunctional degradation derivatives comprise biantennary GalNAc-terminated N-glycans, specifically A2GalNAc2.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by Leishmania species parasites such as Leishmaniasis. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Leishmaniasis, or in an amount effective to prevent Leishmaniasis in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The long-term method for treating or preventing Leishmania disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Leishmaniasis than previously possible.

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

The application belongs to the technical field of organic synthesis chemistry, and particularly relates to an azido tellurium ether derivative and a preparation method and application thereof. In an organic solvent, an olefin, ditelluride and azidotrimethylsilane are used as raw materials, and a stirring reaction is carried out under the presence of a photocatalyst and under the condition of visible light irradiation to obtain the azido tellurium ether derivative. The method has mild reaction conditions, simple operation, high yield and good functional group compatibility, and conforms to the principle of green chemistry. Meanwhile, the azido tellurium ether derivative provided by the application has good inhibitory activity on Leishmania, which provides a drug lead compound for the development of a new type of antiparasitic drug, and has important significance for the prevention and / or treatment of Leishmaniasis.

The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compound of formula (I), the isomeric forms thereof and the salts of same, wherein R1 and R3 are hydrogen and R2 is selected from the list consisting of cyclopentyl, cycloheptyl, 3-methyl-pentyl and adamantane, or wherein R1 and R2 are hydrogen and R3 is selected from the list consisting of cyclopentyl, cyclohexyl and cycloheptyl.